Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors

Neuropsychopharmacology

Volumn 16, Issue 2, 1997, Pages 93-110

  Seeman, Philip ^a   Corbettand, Roy ^c   Van Tol, Hubert H M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SANOFI   (France)

Author keywords

catalepsy; clozapine; dopamine D4 receptors; neuroleptics; Parkinsonism; serotonin2 receptors

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; ISOCLOZAPINE; LOXAPINE; MELPERONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERLAPINE; QUETIAPINE; RACLOPRIDE; RADIOLIGAND; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SPIPERONE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

HUMAN; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

EID: 0031081305     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00187-X     Document Type: Review

References (145)

1. Andén N-E, Stock G (1973): Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346-348
2. Arnt J, Sánchez C, Skarsfeldt T (1994): The so-called atypical antipsychotics - How similar are they? Neuropsychopharmacology 10(suppl 3S):abstr. S103-449
3. 4 receptor repeat: Analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 46:364-373
4. 2 antagonist ritanserin in neurolepticinduced Parkinsonism: A double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13:500-506
5. 2-Receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophrenia Res 15:153-154
6. Bowers Jr MB (1984): Homovanillic acid in caudate and prefrontal cortex following neuroleptics. Eur J Pharmacol 99:103-105
7. Broekkamp CLE, Oosterloo SK, Berendsen HHG, van Delft AML (1988): Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338:191-195
8. 2 dopamine receptor cDNA. Nature 336:783-787
9. Bürki HR, Sayers AC, Ruch W, Asper H (1977): Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Arzneim-Forsch 27: 1561-1565
10. 2 antagonist, ritanserine, and an anticholinergic benztropine on haloperidol-induced dystonia in nonhuman primates. Am Coll Neuropsychopharmacol (Abstr) 30:127
11. Casey DE (1992): The effect of 8-OH-DPAT on haloperidol-induced dystonia in nonhuman primates. Am Coll Neuropsychopharmacol 32:109 (Abstr)
12. Casey DE (1993): Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112:S55-S59
13. Casey DE (1995a): Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 10(suppl 3): 105-114
14. 2 and serotonin mechanisms. In Fog R, Gerlach J, Hemmingsen R (eds), Schizophrenia, Alfred Benzon Symposium 38. Copenhagen, Munksgaard, pp 287-297
15. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
16. Clineschmidt BV, McKendry MA, Papp NL, Pflueger AB, Stone CA, Totaro JA, Williams M (1979): Stereospecific antidopaminergic and anticholinergic actions of the enantimoers of (±)CTC, a derivative of cyproheptadine. J Pharmacol Exp Ther 208:460-467
17. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995): Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-74
18. Creese I, Burt DR, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
19. Daniel D, Targum S, Zimbroff D, Mack R, Zborowski J, Morris D, Sebree T, Wallin B (1995): Efficacy, safety, and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Am Coll Neuropsychopharmacol 34:278 (Abstr)
20. De Jesus OT, Van Moffaert GJC, Dinerstein RJ, Friedman AM (1986); Exogenous 1-DOPA alters spiroperidol binding, in vivo, in the mouse striatum. Life Sci 39:341-349
21. 18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography. Synapse 7:324-327
22. 11C-raclopride and positron emission tomography. J Neurosci 12:3773-3780
23. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356
24. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND, Wolf AP (1993b): Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 90:11816-11820
25. Dewey SL, Smith GS, Logan J, Alexoff D, Ding Y-S, King P, Pappas N, Brodie JD, Ashby Jr CR (1995): Serotonergic modulation of striatal dopamine measured with positron emission tomograpghy (PET) and in vivo microdialysis. J Neurosci 15:821-829
26. Dlabac A, Metysova J, Kazdova E, Metys J (1975): VUFB-10032, a potential psychotropic drug from the group of noncataleptic neuroleptics. Activ Nerv Sup (Praha) 17: 217
27. Dubinsky B, McGuire JL, Niemegeers CJE, Janssen PAJ, Weintraub HS, McKenzie BE (1982): Bromperidol, a new butyrophenone neuroleptic: A review. Psychopharmacology 78: 1-7
28. 4 receptor clones depends on the radioligand used. Soc Neurosci Abstr 21:252.1
29. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544
30. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55:1-3
31. Gefvert O, Lindstrom LH, Langstrom B, Bergstrom M, Lundberg T, Yates RA, Larsson SD, Tuersley MD (1995): Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroque (ICI 204,636) TID. Am Coll Neuropsychopharmacol 34:276
32. 2 dopamine receptors from the high-to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide. J Neurochem 44:1925-1935
33. Gustafsson B, Christensson E (1990): Amperozide - a new putatively antipsychotic drug writh a limbic mode of action on dopamine mediated behaviour. Pharmacol Toxicol (suppl 1): 12-17
34. Hicks PB (1990): The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47:1609-1615
35. 2 antagonistic actions. Jpn J Pharmacol 53:321-329
36. Högberg T, Bengtsson S, de Paulis T, Johansson L, Ström P, Hall H, Ögren SO (1990): Potential antipsychotic agents. 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicyl-amides and related compounds. J Med Chem 33:1155-1163
37. 3 recognition sites: Fact or artifact? Eur J Pharmacol 171: 137-139
38. Hunziker F, Fischer R, Kipfer P, Schmutz J, Burki HR, Eichenberger E, White T (1981): Neuroleptic piperizinyl derivatives of 10H-thieno[3,2-c][l]benzazepines and 4H-thieno[2,3-c][l]benzazepines. Eur J Med Chem - Chim Ther 16:391-398
39. Huttunen M (1995): The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 15(suppl 1): 4S-10S
40. 2 receptor in nonhuman primates. Synapse 10:177-184
41. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518
42. Janssen PAJ, Niemegeers CJE, Schellekens KHL (1965): Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? I: "Neuroleptic activity spectra" for rats. Arzneim-Forsch 15:104-117
43. 3H]neuroleptic binding. Eur J Pharmacol 144:163-171
44. Jaskiw GE, Ubogy D, Meltzer HY (1994): Clozapine's inability to induce experimental catalepsy is not altered by changes in serotonergic transmission. Soc Neurosci Abstr 20:225
45. Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
46. 2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm 86:163-173
47. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM (1992): Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51:55-64
48. 4 receptor in schizophrenia: An update. Psychological Med 26:221-227
49. 4 receptor as potential antipsychotic agents. Am Chem Soc Div Med Chem 211 :abst 113
50. 1C receptor antagonists. Eur J Pharmacol 245: 179-182
51. 3H]clozapine binding sites in rat brain. J Neural Transm 101:51-64
52. 4 receptors in rat frontal cortex. J Neural Transm 101:231-235
53. Kwant WO, Seeman P (1969): The displacement of membrane calcium by a local anesthetic (chlorpromazine). Biochim Biophys Acta 193:338-349
54. Kwant WO, Seeman P (1971): Chlorpromazine adsorption to brain regions. Biochem Pharmacol 20:2089-2091
55. 2-Family receptor distribution in human postmortem tissue: An autoradiographic study. NeuroReport 6:2505-2512
56. 4 receptors in human postmortem brain sections: Comparison between normals and schizophrenics. Schizophrenia Res 18:173
57. 3H]-NGD-94-1. Schizophrenia Res 18:173
58. Laruelle M, Abi-Dargham A, Van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS. Hoffer PB, Kung HF, Innis RB (1995a): SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190
59. Laruelle M, Abi-Dargham A, Gil R, Van Dyck CH, Erdos J, D'Souza D, Rosenblatt W, McChance-Katz E, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Hoffer PB, Krystal J, Charney DS, Innis RB (1995b): SPECT imaging of synaptic dopamine release in drug free schizophrenic patients. Amer Coll Neuropsychol (Abstr) 34:159
60. 1A receptors. Eur J Pharmacol 260:79-83
61. 2 receptor studies. Neuropsychopharmacology 3:361-369
62. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301-314
63. 2-antagonism: A crucial factor for the treatment of schizophrenia. Neuropsychopharmacology 10 (Suppl 3):467S
64. 18F]N-methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons. Synapse 9:195-207
65. 18FESP. In Brunello N, Mendlewicz J, Racagni G (eds), New Generation of Antipsychotic Drugs: Novel Mechanisms of Action, vol. 4. Basel, International Academy for Biomedical Drug Research, Karger, pp 130-135
66. 3 receptors. Mol Pharmacol 43:749-754
67. 2 receptors; evidence for identical binding sites. Eur J Pharmacol 303:123-128
68. 2 receptors. J Neural Transm 130:17-30
69. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exper Ther 265:498-508
70. 4 receptor. Mol Brain Res 29:157-162
71. Megens AAHP, Awouters FHL, Meert TF, Schellekens KHL, Niemegeers CJE, Janssen PAJ (1992): Pharmacological profile of the new potent neuroleptic ocaperidone (R 79 598). J Pharmacol Exp Ther 260:146-159
72. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
73. Meltzer HY (1995): The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 15 (Suppl 1):2S-3S
74. Meltzer HY, Nash JF (1991): Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
75. i values. J Pharmacol Exper Ther 251:238-246
76. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392
77. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995): Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's Disease. Neuropsychopharmacology 12:39-45
78. Miller CH, Hummer M, Pycha R, Fleischhacker WW (1992): The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: Case Reports. Prog Neuro-psychopharmacol Biol Psychiatr 16:247-251
79. Moore NA, Tye NC, Axton MS, Risius FC (1992): The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
80. Munson PJ, Rodbard D (1988): An exact correction to the "Cheng-Prusoff" correction. J Receptor Res 8:533-546
81. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 15:2186-2191
82. Neal-Beliveau BS, Joyce JN, Lucki I (1993): Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exper Ther 265:207-217
83. 1A receptors. Neuropharmacology 35:119-121
84. 3H-YM-09151-2. Naunyn-Schmiedberg's Arch Pharmacol 329:333-343
85. Nordström A-L (1994): The mechanism of antipsychotic drug action examined by PET in schizophrenic patients. Neuropsychopharmacology 10 (Suppl 3, Part 1):695S
86. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152:173-178
87. O'Dowd BF, Nguyen T, Tirpak A, Jarvie KR, Israel Y, Seeman P, Niznik HB (1990): Cloning of two additional catecholamine receptors from rat brain. FEBS Letts 262:8-12
88. Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen N-A, Refshammer C, Sorensen J, Bysted M, Christensen J, Rosenberg R (1995): Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 117:371-378
89. 4 dopamine receptors. Canad J Physiol Pharmacol 72 (Suppl 1): 383.
90. Pehek EA (1995): Systemic and intracortical administration of ritanserin increases in vivo dopamine release in rat prefrontal cortex. Schizophrenia Res 15:161
91. 2 dopamine receptors in bovine brain. Biochem Pharmacol 41:R9-R12
92. 4 receptors in drug-treated schizophrenia. Eur J Pharmacol 281:R5-R6
93. Ross SB (1991): Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56:22-29
94. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma Jr FJ, Shen Y, Meltzer HY, Sibley DR (1994): Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exper Ther 268:1403-1410
95. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368
96. Rupard JH, de Paulis T, Janowsky A, Smith HE (1989): Sterically hindered 5,1-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem 32:2261-2268
97. 3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exper Therap 275:1239-1246
98. Sayers AC, Bürki HR, Ruch W, Asper H (1975): Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia 41:97-104
99. Schmutz J (1973): Absicht und Zufall in der Arznmittelforschung, dargelegt am beispiel der trizyklischen psychopharmaka. Pharmaceut. Acta Helv 48:117-132
100. Schmutz J, Eichenberger E (1992): Clozapine. In Bindra JS, Lednicer D (eds), Chronicles of Drug Discovery, vol 1, New York, John Wiley, pp 39-59
101. 4 receptors by two-fold in rats. Eur J Pharmacol Mol Pharmacol Sect 289:67-72
102. Seeman P (1966a): Erythrocyte membrane stabilization by local anesthetics and tranquilizers. Biochem Pharmacol 15:1737-1752
103. Seeman P (1966b): Membrane stabilization by drugs: Tranquilizers, steroids and anesthetics. Int Rev Neurobiol 9: 145-221
104. Seeman P (1972): The membrane actions of anesthetics and tranquilizers. Pharmacol Rev 24:583-655
105. Seeman P (1990): Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand 82 (Suppl 358):14-20
106. Seeman P (1992a): Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2, clozapine occupies D4. Neuropsychopharmacology 7:261-284
107. Seeman P (1992b): Receptor selectivities of atypical neuroleptics. In Meltzer HY (ed), Novel Antipsychotic Drugs. New York, Raven Press Ltd, pp 145-154
108. Seeman P (1995a): Dopamine receptors and psychosis. [Scientific American] Science and Medicine 2(5):28-37
109. Seeman P (1995b): Therapeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 10 (Suppl 3):5-13
110. Seeman P (1995c): Dopamine receptors. Clinical correlates. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The fourth generation of progress. New York, Raven Press, pp 295-302
111. Seeman P, Bialy HS (1963): The surface activity of tranquilizers. Biochem Pharmacol 12:1181-1191
112. Seeman P, Weinstein J (1966): Erythrocyte membrane stabilization by tranquilizers and antihistamines. Biochem Pharmacol 15:1737-1752
113. Seeman P, Kwant WO (1969): Membrane expansion of the erythrocyte membrane by both the neutral and ionized forms of chlorpromazine. Biochim Biophys Acta 183:512-519
114. 4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol -Mol Pharmacol Section 291:59-66
115. Seeman P, Wong M, Lee T (1974): Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers. Fed Proc 33:246
116. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975): Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci U S A 72:4376-4380
117. Seeman P, Lee T, Chau-Wong M, Wong K (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719
118. 3H-spiperone depend on tissue concentration: analysis and examples. J Neurochem 43:221-235
119. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97
120. Seeman P, Niznik HB, Guan H-C, Booth G, Ulpian C (1989b): Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Nat Acad Sci U S A 86:10156-10160
121. 2 receptor reveals different densities for dopamine antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol Mol Pharmacol Sect 227:139-146
122. Seeman P, Guan H-C, Van Tol HHM (1993): Dopamine D4 receptors are elevated in schizophrenia. Nature 365:441-445
123. 125I]epidepride. Eur J Pharmacol 286:R3-R5
124. Seeman P, Corbett R, Nam D, Van Tol HHM (1996): Dopamine and serotonin receptors: Amino acid sequences, and clinical role in neuroleptic Parkinsonism. Jpn J Pharmacol 71:187-204
125. Smith GS, Dewey SL, Logan J, Brodie JD, Vitkun S, Simkowitz P, Alexoff D, Fowler JS, Volkow ND, Wolf AP (1994): The serotonin-dopamine interaction measured with positron emission tomography (PET) and C-11 raclopride in normal human subjects. J Nucl Med 35:85P
126. Snyder S, Greenberg D, Yamamura HI (1974): Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiat 31:58-61
127. Stille G, Lauener H, Eichenberger E, Hunziker F, Schmutz J (1965a): Über eine neue chemische gruppe stark wirksamer neuroleptica. 5. Mittelung uber siebengliederige heterocylclen. Arzneim-Forsch 15:841-843
128. Stille G, Ackermann H, Eichenberger E, Lauener H (1965b): The pharmacological properties of a potent neurotropic compound from the dibenzothiazepine group. Int J Neuropharmacol 4:375-391
129. 2 receptors. J Pharmacol Exper Ther 266:1374-1384
130. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 681:109-116
131. Tallman JF (1994): NGD 94-1: Preclinical profile of a specific dopamine-4 (D4)-receptor antagonist. Amer Coll Neuropsychopharmacology 33:31
132. 2-like receptors are elevated after chronic treatment with typical and atypical neuroleptics. Schizophrenia Res 15:168
133. 4 antagonist. Am Chem Soc Div Med Chem 211:abstract 114
134. Usuda S, Nishikori K, Noshiro O, Maeno H (1981): Neuroleptic properties of cis-N-(1-benzyl-2-methyl-pyrrolidin-3yl)-5-chloro-2-methoxy4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity. Psychopharmacology 73:103-109
135. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350:614-619
136. Van Tol HHM, Wu CM, Guan H-C, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992): Multiple dopamine D4 receptor variants in the human population. Nature 358:149-152
137. Wadenberg M-L (1992): Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm 89:49-59
138. Wadenberg ML, Ahlenius S (1991): Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83:43-53
139. Wallin B, Holgate KL, Sebree T, Zborowski J, Schmitz P, van Kammen D (1995): Two open-label, long-term safety studies of sertindole. Amer College Neuropsychopharmacol 34:278
140. 2 receptors of normal human brain in vitro. Eur J Pharmacol 143:279-282
141. 2 receptors by magnesium and sodium ions J Neurochem 45: 1842-1849
142. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper TB (1989): Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 46:482-483
143. Wong DF, Hong C, Yokoi F, Grunder G, Schlaepfer T, Szymanski S, Imperial A, Pearlson G, Nestadt G, Ravert H, Dannals R, Angrist B, Gjedde A (1995): Quantification of human intrasynaptic dopamine release by iv cocaine and amphetamine. Amer Coll Neuropsychopharmacol 34:227
144. Wreggett KA, Wells JW (1995): Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J Biol Chem 270:22488-22499
145. 3H]raclopride binding in the rat brain. Synapse 9:188-194